The Use of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients With Rheumatoid Arthritis

Epidemiology and Vaccine Prevention
doi 10.31631/2073-3046-2015-14-4-67-73
Full Text
Abstract

Available in full text

Date
Authors
Publisher

LLC Numicom

Related search

Efficacy and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients With Rheumatoid Arthritis

The Clinician
2015English

Effect of Abatacept on the Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccination (PPSV23) in Rheumatoid Arthritis Patients

Arthritis Research and Therapy
RheumatologyAllergyImmunology
2015English

Assessment of Clinical and Immunological Efficacy and Safety of 23-Valent Pneumococcal Vaccine in Patients With Rheumatoid Arthritis

Pulmonologiya
PulmonaryRespiratory Medicine
2015English

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices

MMWR. Morbidity and mortality weekly report
Health Information ManagementMutagenesisEpidemiologyHealthMedicineToxicology
2019English

Immunogenicity and Tolerance of a 7-Valent Pneumococcal Conjugate Vaccine in Nonresponders to the 23-Valent Pneumococcal Vaccine

Infection and Immunity
ParasitologyInfectious DiseasesImmunologyMicrobiology
2000English

Recommendations for the Prevention of Streptococcus Pneumoniae Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)

Pediatrics
Child HealthPediatricsPerinatology
2010English

PIN64 Assessing the Cost-Effectiveness (CE) of Vaccinating the Elderly and At-Risk Adults With the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) or No Vaccination (NoVac) in the UK

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

A Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) in Healthy Children, Adults, and Elderly

Human Vaccines and Immunotherapeutics
MedicineAllergyImmunologyPharmacology
2018English

Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis

Pediatrics
Child HealthPediatricsPerinatology
2000English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy